Glepaglutide

Evidence in perspective

Reduction in parenteral support is relevant to short bowel syndrome, but specialist fluid/nutrition management is part of that outcome. The twice-weekly result cannot validate every schedule. A linked corrigendum remains to be reconciled in full.

Who was studied

Patients with short bowel syndrome requiring parenteral support.

What the sources found

A phase 3 trial found reduced parenteral-support needs with twice-weekly treatment.

What remains unknown

Parenteral support must be adjusted under specialist monitoring; findings are not evidence for routine gut wellness use. A linked 2025 corrigendum was identified. Its full content was not accessible in the retrieved record, so the affected details remain under review.

How it works

Activates GLP-2 receptors to support intestinal absorption.

Activates GLP-2 receptors to support intestinal absorption. Parenteral support must be adjusted under specialist monitoring; findings are not evidence for routine gut wellness use.

Human trials

This catalog identifies human research. A trial can be early, small or negative; its existence does not establish approval or benefit for every proposed use. Check the study population and outcomes.

Understanding the evidence

Reported adverse effects

• Earlier trial reports included stoma complications, injection reactions, edema, nausea and abdominal pain.